GlassScriptPhysician profile
Ravi K Titha
NPI 1558452482
$3,934.44
in general payments reported to CMS, 2019-2025
22 companies · $716 in 2025
The $716 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $793 · 2021: $872 · 2022: $215 · 2023: $393 · 2024: $530 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,100.44 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $561.33 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $551.13 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Allergan, INC. | $446.84 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.14 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $228.26 | 2019-2020 | |
| Amarin Pharma, INC. | $111.09 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $86.04 | 2021-2023 | |
| Amgen INC. | $77.87 | 2023-2024 | Repatha, Otezla |
| Vifor Pharma, INC. | $75.82 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $64.69 | 2021 | |
| Scilex Pharmaceuticals INC. | $56.48 | 2021-2022 | |
| Pfizer INC. | $54.02 | 2019-2024 | |
| Axsome Therapeutics, INC. | $48.75 | 2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $48.74 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $48.68 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.71 | 2019-2021 | |
| Advanced Oxygen Therapy INC. | $23.11 | 2025 | Topical Oxygen Chamber For Extremities |
| Lilly USA, LLC | $20.85 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.28 | 2023 | Xifaxan |
| Lundbeck LLC | $18.22 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $14.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Titha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.